Cangrelor Arm vs Clopidogrel Arm: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
Measures 6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note | Source |
|---|---|---|---|---|---|---|
| Risk in group 1 | 0.0286 | 0.024 | 0.0339 | wilson | ClinicalTrials.gov | |
| Risk in group 2 | 0.0291 | 0.0245 | 0.0345 | wilson | ClinicalTrials.gov | |
| Risk difference, group 1 minus group 2 | -0.000517 | -0.00758 | 0.00654 | newcombe hybrid score | ClinicalTrials.gov | |
| Risk ratio, group 1 over group 2 | 0.982 | 0.77 | 1.25 | log | ClinicalTrials.gov | |
| Odds ratio, group 1 over group 2 | 0.982 | 0.764 | 1.26 | log | ClinicalTrials.gov | |
| Number needed to treat, for one fewer participant with a serious adverse event on Cangrelor Arm than on Clopidogrel Arm | 1,930 | from the risk difference interval | the interval includes no difference | ClinicalTrials.gov |
Groups 2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code | Source |
|---|---|---|---|---|---|---|
| Group 1 | Cangrelor Arm | cangrelor arm: placebo capsules (to match) at PCI start + cangrelor bolus (30 mcg/kg) \& infusion (4mcg/kg/min) followed by clopidogrel (600 mg) post infusion | 125 | 4,374 | EG000 | ClinicalTrials.gov |
| Group 2 | Clopidogrel Arm | clopidogrel arm: clopidogrel capsules (600 mg)at PCI start + placebo bolus \& infusion (to match) followed by placebo capsules post infusion | 127 | 4,365 | EG001 | ClinicalTrials.gov |
Harm 2
| Field | Value | Source |
|---|---|---|
| What it counts | Total, serious adverse events | ClinicalTrials.gov |
| Time frame | ClinicalTrials.gov |
Trial 8
| Field | Value | Source |
|---|---|---|
| Title | A Clinical Trial to Demonstrate the Efficacy of Cangrelor | ClinicalTrials.gov |
| NCT number | NCT00305162 | ClinicalTrials.gov |
| Phases | PHASE3 | ClinicalTrials.gov |
| Conditions | Myocardial Infarction (MI), Acute Coronary Syndromes (ACS) | ClinicalTrials.gov |
| Interventions | Cangrelor (P2Y12 inhibitor), clopidogrel (oral P2Y12 inhibitor), Placebo bolus & placebo infusion, Placebo capsules - end of infusion, Placebo capsules - as soon as possible after randomization | ClinicalTrials.gov |
| Lead sponsor | The Medicines Company | ClinicalTrials.gov |
| Results first posted | 2014-04-23 | ClinicalTrials.gov |
| Results on ClinicalTrials.gov | https://clinicaltrials.gov/study/NCT00305162?tab=results | ClinicalTrials.gov |
Source 4
| Field | Value | Source |
|---|---|---|
| Release | trial-comparisons-2026-03-23-0.1.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57 | ClinicalTrials.gov |
| AACT copy | 2026-03-23 | ClinicalTrials.gov |
| Tables read | outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet | ClinicalTrials.gov |
Release trial-comparisons-2026-03-23-0.1.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.